Yissum - Research Development Company of the Hebrew University

Pepticom

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Investment Opportunities in Startups and Spinoffs · Israel

Summary of the technology

Pepticom
Project ID : 26-2014-3056

Yissum - Research Development Company of the Hebrew University

Description of the technology

COVID-19

Pepticom is implementing its proprietary core AI technology on various Coronavirus proteins and the ACE2 to identify novel inhibitors that can fight Sars Cov2. They are currently looking for partners to validate and develop these peptide drug candidates.

Company Name

Pepticom

Year Company was Founded

2013

Company Founders

Pepticom emerged out of Prof. Amiram Goldblum laboratory in the Hebrew University of Jerusalem with a team of multidisciplinary PhD scientists and business entrepreneurs.

Current CEO

Dr. Immanuel Lerner

About the Company

Pepticom is the leader in the emerging field of AI for peptide design that allow pharma companies to accelerate innovative molecules design and discovery while reducing the time, costs and risks involved.

Pepticom’s proprietary technology enables the design and discovery of advanced peptide-based drug candidates quickly and comprehensively. Pepticom's computational drug design overcomes the limitations of existing display techniques through reinforcement learning methodology.

Pepticom has several ongoing collaboration and pilot projects to design and develop new active products with leading Pharma/Biotech’s and Agriculture companies.

  • Toll-Like Receptor (TLR) modulating peptides. Wide range of agonists and antagonists discovered, with potential usage in novel vaccination technologies.

Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity, Amit Micaheli et al.,J Immunol. 2018 Dec 1;201(11):3383-3391

  • Pro-bono project in the area of ultra-rare disease: Adult Polyglucosan Body Disease, revolutionary peptide developed for stabilizing of mutant Glycogen branching enzyme 1 (GBE1).

Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design, Sean Froese et al., Human Molecular Genetics, 2015, Vol. 24, No. 20 5667–5676

Links to Products

Pepticom has its own development program -- two validated drug targets with several peptide leads molecules (all are small cyclic with non-natural AA modifications).

Development Milestones

  • 2013-2020: The company developed its core technology and applied it in commercial collaborations.
  • 2020 Raised $5 Million in Series A Funding in

Target Market

Pharma Companies: Pepticom is looking to partner with companies engaged in peptide discovery and development. The company’s AI peptide design platform can augment the drug discovery and development process.

Selected collaborators:

ADAMA

Fraunhofer institute

The Hebrew University

Hadassah Medical center

Oxford University

Stuttgart University

Company Website

http://www.pepticom.com/

Social Media Links

https://www.linkedin.com/company/pepticom-ltd./

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Amiram Goldblum
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Pharmaceutical Products / Drugs
  • Bioinformatics Technology
  • Socio-economic development models, economic aspects
  • Genetic Engineering / Molecular Biology
  • Bioinformatics Market
  • Medical Health related
  • Molecular diagnosis
  • In-vitro diagnostics
  • Therapeutic
  • Other (uncategorised)
  • covid-19

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.